100 likes | 252 Views
Periocular Drug Delivery. Wednesday June 27. 2012 Cheryl Jennings, Bria Dawson, Even Skjervold , & Kali Luffy. Overview. Casted two films with FDA Completed calibration curves for FDA Tested solvents for both drugs Casted 4 films; two for ganciclovir and two for valganciclovir
E N D
Periocular Drug Delivery Wednesday June 27. 2012 Cheryl Jennings, Bria Dawson, Even Skjervold, & Kali Luffy
Overview • Casted two films with FDA • Completed calibration curves for FDA • Tested solvents for both drugs • Casted 4 films; two for ganciclovir and two for valganciclovir • Started drug release study for FDA
Concentration : 1-10 µg/ml FDA Serial Dilution 1 FDA Serial Dilution 2 S/N=809.74 S/N values are not available
Concentration : 0.1-1 µg/ml FDA Serial Dilution 1 FDA Serial Dilution 2 S/N=656.91 S/N values are not available
Concentration : 0.1-0.01 µg/ml FDA Serial Dilution 1 FDA Serial Dilution 2 S/N=12.08 S/N values are not available
Concentration : 0.01-0.001 µg/ml FDA Serial Dilution 1 FDA Serial Dilution 2 S/N=317.29 S/N values are not available
Solvent study for Ganciclovir & Valganciclovir *In heat bath at boiling
pH Study for maximum flouresence of Ganciclovir & Valganciclovir pH: 1-5 Concentration : 10 µg/ml S/N=11.4 (G) 7.4 (V) at pH 1, <1 after pH 2.5
pH Study for maximum flouresence of Ganciclovir & Valganciclovir pH: 0.2-1 Concentration : 10 µg/ml S/N=7.5
Timeline • Complete calibration curves for ganciclovir & valganciclovir • Complete drug release study for films with ganciclovir & valganciclovir • Characterize films